Key result
Intermuscular implantation of the S-ICD resulted in 0% incidence of dislocations, infections, hematoma formations, or skin erosions over a mean follow-up of 9 months.
Why the study?
Does intermuscular placement of the S-ICD provide a safe alternative to standard subcutaneous placement in patients with ventricular arrhythmias?
Observational (n=14)
No
Does intermuscular placement of the S-ICD provide a safe alternative to standard subcutaneous placement in patients with ventricular arrhythmias?
Intermuscular implantation of the S-ICD between the serratus anterior and latissimus dorsi muscles appears to be a safe alternative to standard subcutaneous placement, with no complications observed over 9 months in a small cohort.
Intermuscular S-ICD placement appears feasible short-term; hypothesis-generating and requires prospective validation before practice change.
The subcutaneous implantable cardioverter defibrillator (S-ICD) is a novel device now accepted in clinical practice for treating ventricular arrhythmias. In 14 consecutive patients, S-ICD devices were placed in the virtual space between the anterior surface of the serratus anterior muscle and the posterior surface of the latissimus dorsi muscle. During a mean follow up of 9 months, no dislocations, infections, hematoma formations, or skin erosions were observed. Intermuscular implantation of the S-ICD could be a reliable, safe, and appealing alternative to the standard subcutaneous placement.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2016) conducted an observational in Ventricular arrhythmias (n=14). Intermuscular implantation of S-ICD was evaluated on Dislocations, infections, hematoma formations, or skin erosions. Intermuscular implantation of the S-ICD resulted in 0% incidence of dislocations, infections, hematoma formations, or skin erosions over a mean follow-up of 9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: